Long-term efficacy of human papillomavirus vaccination

Gynecologic Oncology

Volumn 107, Issue 2 SUPPL., 2007, Pages

  Ault, Kevin A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Human papillomavirus vaccination; Immune memory

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HUMORAL IMMUNITY; IMMUNOLOGICAL MEMORY; LONG TERM CARE; LYMPHOCYTE PROLIFERATION; MATHEMATICAL MODEL; NONHUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; UTERINE CERVIX DYSPLASIA; VACCINATION; WOMEN'S HEALTH;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; B-LYMPHOCYTES; FEMALE; HEPATITIS B VACCINES; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOLOGIC MEMORY; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 35148871799     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.07.078     Document Type: Article

References (22)

1. Banatvala J., Van Damme P., and Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 19 (2001) 877-885
2. Leclerc C., Sedlik C., Lo-Man R., Charlot B., Rojas M., and Derlaund E. Stimulation of a memory B cell response does not require primed helper T cells. Eur J Immunol 25 (1995) 2533-2538
3. Zinkernagel R.M., Bachmann M.F., Kundig T.M., Oehen S., Pirchet H., and Hengartner H. On immunological memory. Ann Rev Immunol 14 (1996) 33-67
4. McHeyzer-Williams L.J., and McHeyzer-Williams M.G. Antigen-specific memory B cell development. Ann Rev Immunol 23 (2005) 487-513
5. European Consensus Group on Hepatitis B Immunity. Are booster immunizations needed for lifelong hepatitis B immunity. Lancet 355 (2002) 561-565
6. Koff R. Immunogenicity of hepatitis B vaccines: implications of immune memory. Vaccine 20 (2002) 3695-3701
7. Harper D.M., Franco E.L., Wheeler C.M., Moscicki B., Rateli-Martins C., Jenkins D., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from randomised control trial. Lancet 367 (2006) 1247-1255
8. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New Eng J Med 356 19 (2007) 1928-1943
9. Villa L.L., Costa R.L.R., Petta C.A., Andrade R.P., Paavonen J., Iversen O.-E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 (2006) 1459-1466
10. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV 16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24 (2006) 5937-5949
11. Olsson S.-E., Villa L.L., Costa R.L.R., Petta C.A., Andrade R.P., Malm C., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25 (2007) 4931-4939
12. Caulfield M.J., Shi L., Wang S., Wang B., Tobery T.W., Mach H., et al. Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice. Hum Vaccin 3 4 (2007) [Epub ahead of print]
13. Fraser C., Tomassini J.E., Xi L., Golm G., Watson M., Giuliano A., et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 25 (2007) 4324-4333
14. Emeny R.T., Wheeler C.M., Jansen K.U., Hunt W.C., Fu T.-M., Smith J.F., et al. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol 76 15 (2002) 7832-7842
15. Pinto L.A., Viscidi R., Harro C.D., Kemp T.J., García-Piñeres A.J., Trivett M., et al. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology 353 2 (2006) 451-462
16. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New Eng J Med 356 19 (2007) 1915-1927
17. Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 (2007) 1861-1868
18. Lehtinen M., Kibur M., Luostarinen T., Anttila A., and Pukkala. Prospects for phase III-IV HPV vaccination trials in the Nordic countries and in Estonia. J Clin Virol 19 (2000) 113-122
19. Lehtinen M., Herrero R., Mayaud P., Barnabad R., Dillner J., Paavonen J., et al. Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 24S3 (2006) S3233-S3241
20. Lehtinen M., Idänpään-Heikkilä I., Palmroth J., Barr E., Cacciatore R., et al. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Int J STD AIDS 17 4 (2006) 237-246
21. Pavonen J., Jenkins D., Bosch F.X., Naud P., Salmerón J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 (2007) 2161-2170
22. Lehtinen M., Apter D., Dubin G., Kosunen E., Isaksson R., Korpivaara E.L., et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS 17 8 (2006) 517-521